FY2024 EPS Estimates for TransCode Therapeutics, Inc. Boosted by Analyst (NASDAQ:RNAZ)

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) – Analysts at HC Wainwright increased their FY2024 earnings per share estimates for TransCode Therapeutics in a research note issued on Wednesday, April 3rd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($2.14) per share for the year, up from their prior estimate of ($25.20). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.49) EPS and FY2027 earnings at ($0.46) EPS.

TransCode Therapeutics Stock Performance

RNAZ opened at $0.64 on Monday. The company has a market cap of $403,326.00, a PE ratio of 0.00 and a beta of -0.35. TransCode Therapeutics has a 1 year low of $0.56 and a 1 year high of $356.00. The firm has a 50 day moving average price of $0.68 and a 200 day moving average price of $7.68.

Hedge Funds Weigh In On TransCode Therapeutics

A number of hedge funds have recently made changes to their positions in RNAZ. Worth Venture Partners LLC raised its position in TransCode Therapeutics by 9.7% in the first quarter. Worth Venture Partners LLC now owns 324,157 shares of the company’s stock valued at $934,000 after purchasing an additional 28,617 shares during the period. Renaissance Technologies LLC acquired a new position in TransCode Therapeutics during the 2nd quarter worth approximately $25,000. UBS Group AG purchased a new position in TransCode Therapeutics in the 3rd quarter worth approximately $74,000. Sabby Management LLC grew its position in TransCode Therapeutics by 32.8% in the third quarter. Sabby Management LLC now owns 250,309 shares of the company’s stock valued at $126,000 after acquiring an additional 61,872 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of TransCode Therapeutics during the fourth quarter valued at approximately $46,000.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.